Observational follow‐up of the PROactive Study: a 6‐year update
ConclusionsThese data suggest that improved macrovascular outcomes seen with pioglitazone subside without continued pioglitazone treatment. The double‐blind period bladder cancer imbalance did not persist in follow‐up.
Source: Diabetes, Obesity and Metabolism - Category: Endocrinology Authors: Erland Erdmann, Eric Song, Robert Spanheimer, Anne‐Ruth van Troostenburg de Bruyn, Alfonso Perez Tags: Original Paper Source Type: research
More News: Actos | Bladder Cancer | Cancer | Cancer & Oncology | Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Eyes | Obesity | Statistics | Stroke | Study